AUS
NZ
UK
CA
USA
IND
Healthcare
Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infection Gel in Indonesia
December 09, 2024 11:34 AM AEDT| By Team Kalkine MediaHighlights,Milestone Approval,: Recce Pharmaceuticals gains Indonesian regulatory and ethics approval for Phase 3 trial of its gel, RECCE 327 (R327G).,Focus on Diabetes,: Indonesia’s diabetes crisis underscores the urgency, with nearly 20 million aff...
Sonic Healthcare Expands in Europe with €423M Acquisition of German Lab Group
December 09, 2024 11:30 AM AEDT| By Team Kalkine MediaHighlights,Major Acquisition,: Sonic Healthcare Ltd acquires Laboratory Group Dr. Kramer & Colleagues (LADR), one of Germany's top five medical lab groups.,Strategic Value,: LADR’s expected CY 2024 revenue is €370 million (~AU$610 million), aligning...
Recce Pharmaceuticals (ASX:RCE) Gains Phase 3 Trial Approval in Indonesia
December 09, 2024 11:22 AM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals (RCE) receives approval for a Phase 3 trial in Indonesia targeting diabetic foot infections.,Indonesia's rising diabetes rates make it a strategic location for Recce's innovative treatment.,The trial builds on the com...
ResMed (ASX: RMD) Shares Growth: What’s Driving the Success?
December 06, 2024 03:31 PM AEDT| By Team Kalkine MediaHighlights,ResMed’s revenue grew 12% in FY24, bolstered by its obstructive sleep apnoea (OSA) products.,Patient enrolment in ResMed’s myAir app surged 28% year-over-year, driving growth.,Analysts project 20% earnings growth by FY27, with ResMed tradi...
ASX 200 Mining Stocks Struggling in 2024, But What’s Ahead for 2025?
December 06, 2024 03:19 PM AEDT| By Team Kalkine MediaHighlights,ResMed’s revenue grew 12% in FY24, bolstered by its obstructive sleep apnoea (OSA) products.,Patient enrolment in ResMed’s myAir app surged 28% year-over-year, driving growth.,Analysts project 20% earnings growth by FY27, with ResMed tradi...
CleanSpace Holdings Shares Jump 15.7% Following CEO Appointment Announcement
December 06, 2024 12:04 PM AEDT| By Team Kalkine MediaHighlights,Share Price Surge:,CleanSpace Holdings climbed 15.7% to 40.5 cents during morning trading on Friday.,New CEO Announcement:,Gabrielle O’Carroll, a seasoned executive with 18 years at 3M, will assume the role of CEO starting January 1, 2025....
AstraZeneca Orders Four More APAS Units from Clever Culture Systems
December 05, 2024 07:48 PM AEDT| By Team Kalkine MediaHighlights,AstraZeneca orders four more microbiological scanners from Clever Culture Systems.,The $3M order includes seven years of support and maintenance.,APAS system integration expands across AstraZeneca’s global operations.,In a significant deve...
Memphasys Ships Felix Sperm Separator Unit to Dubai
December 05, 2024 02:24 PM AEDT| By Team Kalkine MediaHighlights:,Memphasys,Ltd. (,ASX:MEM,),has delivered a demonstration unit of its Felix sperm separator system to a Dubai hospital for evaluation.,The Felix system,utilizes,electrophoresis technology to isolate sperm from semen for artificial insemina...
Island Pharmaceuticals Advances Dengue Fever Treatment with Promising PROTECT Clinical Trial Results
December 05, 2024 01:23 PM AEDT| By Team Kalkine MediaHighlights:,Encouraging Progress in Dengue Research:,Island Pharmaceuticals (,ASX:ILA,) has announced promising results from its PROTECT clinical trial, targeting the prevention and treatment of Dengue fever, which affects 400 million people annually...
Clever Culture Systems Lands $3M Order from AstraZeneca, Shares Surge 23.53%
December 05, 2024 01:11 PM AEDT| By Team Kalkine MediaHighlights,AstraZeneca Order Expansion:,AstraZeneca’s latest order brings the total number of APAS units purchased to 12.,APAS Technology:,The system automates imaging and analysis of microbiological cultures on laboratory plates and was first offere...
Lumos Diagnostics Shares Surge 22.6% on Milestone Approval for FebriDx Reimbursement
December 05, 2024 12:47 PM AEDT| By Team Kalkine MediaHighlights,CMS Approval:,FebriDx received a PLA code (0442U) with reimbursement set at US$41.38 per test, effective January 2025.,Unique Diagnostic Tool:,FebriDx distinguishes bacterial from non-bacterial infections, addressing antibiotic overprescri...
AstraZeneca Expands Partnership with Clever Culture Systems (ASX:CC5) Through $3M APAS Order
December 05, 2024 11:29 AM AEDT| By Team Kalkine MediaHighlights:,Clever Culture Systems Secures AstraZeneca Order:,AstraZeneca placed an order for four,additional,APAS microbiological scanners from Clever Culture Systems (ASX:CC5) valued at $3 million over seven years, including maintenance and support...
Anatara’s IBS Treatment Trial Achieves Key Recruitment Milestone
December 04, 2024 02:58 PM AEDT| By Team Kalkine MediaHighlights,Anatara,Lifesciences (ANR) completes participant recruitment for Stage 2 of its IBS treatment trial,.,Recruitment spans four sites across Australia with screening set to continue,.,Headline results,anticipated,in the first quarter of 2025,...
Invion Begins Clinical Trials for Promising Skin Cancer Treatment INV043
December 03, 2024 12:24 PM AEDT| By Team Kalkine MediaHighlights,Invion,(IVX),commences,trials for its advanced cancer treatment, INV043,.,The trial explores non-invasive therapy for non-melanoma skin cancer,.,Pre-clinical research suggests potential benefits of INV043 in cancer treatment,.,Invion (ASX:...
Percheron Therapeutics Expands US Market Presence with OTCQB Uplisting
December 03, 2024 11:04 AM AEDT| By Team Kalkine MediaHighlights,Percheron Therapeutics uplisted its shares to the OTCQB,market..,American Depository Receipt (ADR) program,terminated,to streamline US trading,.,The uplisting aligns with Australian compliance standards, ensuring efficiency,.,Australian bi...
Avicursen Trial Milestone Approaches for Duchenne Muscular Dystrophy
December 02, 2024 03:08 PM AEDT| By Team Kalkine MediaHighlights,Percheron Therapeutics (PER) gears up for key trial data announcement on,avicursen,.,Data focuses on Duchenne muscular dystrophy, an inherited degenerative muscle condition,.,Full data release scheduled for mid-December, assessing six-mont...
Why are Orthocell Ltd (ASX: OCC) Shares Soaring 26% on ASX Today?
December 02, 2024 02:19 PM AEDT| By Team Kalkine MediaHighlights:,Orthocell Reports Successful Completion of Remplir 510(k) Nerve Repair Study,U.S. FDA Clearance Expected in Q1 2025 Following Study Results,Study Validates Remplir as Safe and Effective for Peripheral Nerve Repair,Orthocell Ltd (ASX: OCC)...
Orthocell Achieves Key Milestone for US Approval of Nerve Repair Solution
December 02, 2024 12:38 PM AEDT| By Team Kalkine MediaHighlights,Orthocell,(OCC) completes pivotal US FDA 510(k) study for nerve repair product,Remplir,.,Study confirms,Remplir's,safety and effectiveness, enabling US marketing application submission.,Anticipated,US FDA clearance set for the first quarte...
Revolutionizing Respiratory Imaging: 4DMedical (ASX:4DX) Expands in Western Australia
December 02, 2024 12:32 PM AEDT| By Team Kalkine MediaHighlights,4DMedical (4DX) teams up with Perth Radiological Clinic for advanced respiratory imaging,.,XV Technology enables early detection of lung function issues,.,Partnership introduces,cutting-edge,diagnostics to the Perth community,.,4DMedical (...
Syntara’s (ASX:SNT) Strong Annual Performance Despite Revenue Decline
December 02, 2024 12:02 PM AEDT| By Team Kalkine MediaHighlights,Syntara's (SNT) annual return reaches 87%, outperforming market trends,.,Revenue declines by 7.5% despite strong share price growth,.,The stock shows a mixed performance over longer,timeframes,.,While market-wide trends often guide index f...
Advertise your brand on Kalkine Media